Merck Sharp & Dohme MK-8931-019
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD)
